Axsome Therapeutics AXSM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $708.24M+10.9% | $638.5M+13.8% | $561.26M+13.4% | $495.03M+14.5% | $432.16M+12.0% | ||
| $52.41M+10.4% | $47.48M+4.0% | $45.66M+8.2% | $42.19M+14.7% | $36.8M+10.5% | ||
| $655.82M+11.0% | $591.02M+14.6% | $515.6M+13.9% | $452.85M+14.5% | $395.36M+12.2% | ||
| 92.6%0.0pp | 92.6%+0.7pp | 91.9%+0.4pp | 91.5%0.0pp | 91.5%+0.1pp | ||
| $191.17M+4.3% | $183.28M-3.3% | $189.49M-2.7% | $194.72M-0.2% | $195.03M+4.3% | ||
| $634.81M+11.3% | $570.6M+10.9% | $514.57M+11.9% | $459.9M+6.2% | $433.18M+5.3% | ||
| $6.38M0.0% | $6.38M0.0% | $6.38M0.0% | $6.37M0.0% | $6.38M-0.3% | ||
| $881.37M+9.5% | $805.26M+4.1% | $773.69M+6.9% | $723.97M+3.1% | $702.43M+5.4% | ||
| -$173.14M-3.8% | -$166.76M+21.5% | -$212.42M+7.2% | -$228.94M+15.3% | -$270.27M+3.7% | ||
| -24.4%+1.7pp | -26.1%+11.7pp | -37.8%+8.4pp | -46.2%+16.3pp | -62.5%+10.2pp | ||
| -$5.31M+19.0% | -$6.56M+13.7% | -$7.6M+10.2% | -$8.45M-6.8% | -$7.92M-20.5% | ||
| -$188.83M-2.8% | -$183.7M+20.3% | -$230.4M+7.0% | -$247.78M+10.9% | -$278.19M+3.1% | ||
| —— | —— | -$875K0.0% | -$875K-1,129% | $85K0.0% | ||
| -$188.3M-2.8% | -$183.17M+20.2% | -$229.53M+7.0% | -$246.9M+11.3% | -$278.27M+3.1% | ||
| -26.6%+2.1pp | -28.7%+12.2pp | -40.9%+9.0pp | -49.9%+14.5pp | -64.4%+10.1pp | ||
| -$3.72-1.1% | -$3.68+21.2% | -$4.67+7.9% | -$5.07+12.1% | -$5.77+3.7% | ||
| -$3.72-1.1% | -$3.68+21.2% | -$4.67+7.9% | -$5.07+12.1% | -$5.77+3.7% | ||
| 200.4M+1.2% | 198.1M+0.9% | 196.2M+1.0% | 194.4M+1.0% | 192.5M+0.8% | ||
| 200.4M+1.2% | 198.1M+0.9% | 196.2M+1.0% | 194.4M+1.0% | 192.5M+0.8% | ||
| -$3.4M-37.3% | -$2.47M-114% | $17.58M-15.4% | $20.79M-33.1% | $31.05M+10.4% | ||
| $6.38M0.0% | $6.38M0.0% | $6.38M0.0% | $6.37M0.0% | $6.38M-0.3% | ||
| -$5.31M+19.0% | -$6.56M+13.7% | -$7.6M+10.2% | -$8.45M-6.8% | -$7.92M-20.5% | ||
| $708.24M+10.9% | $638.5M+13.8% | $561.26M+13.4% | $495.03M+14.5% | $432.16M+12.0% | ||
| -$173.14M-3.8% | -$166.76M+21.5% | -$212.42M+7.2% | -$228.94M+15.3% | -$270.27M+3.7% | ||
| -$166.29M-4.0% | -$159.88M+22.2% | -$205.53M+7.4% | -$222.03M+15.7% | -$263.35M+3.8% | ||
| -$166.29M-4.0% | -$159.88M+22.2% | -$205.53M+7.4% | -$222.03M+15.7% | -$263.35M+3.8% | ||
| -23.5%+1.6pp | -25%+11.6pp | -36.6%+8.2pp | -44.9%+16.1pp | -60.9%+10.0pp | ||
| -$173.14M-3.8% | -$166.76M+21.5% | -$212.42M+7.2% | -$228.94M+15.3% | -$270.27M+3.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Axsome Therapeutics's revenue?
- Axsome Therapeutics (AXSM) generated $708.2M in revenue over the trailing twelve months, up 63.9% year over year.
- Is Axsome Therapeutics profitable?
- Axsome Therapeutics is not currently profitable: it reported a net loss of $188.3M over the trailing twelve months, a -26.6% net margin.
- What are Axsome Therapeutics's profit margins?
- Gross margin is 92.6% and operating margin is -24.4%, with a -26.6% net margin.
- What is Axsome Therapeutics's earnings per share?
- Axsome Therapeutics's diluted EPS over the trailing twelve months is $-3.72.
- Where does Axsome Therapeutics's income statement data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
